Tenaya Therapeutics FY2022 net loss $123.7M; TN-201 IND cleared, Phase 1b Q3 2023

Tenaya Therapeutics, Inc.

Net loss of $33.5M ($0.61/share) in Q4 2022 and $123.7M ($2.76/share) in FY2022.
Cash and investments $204.2M at year-end; runway expected into first half 2025.
TN-201 IND for MYBPC3 gene therapy cleared by FDA; Phase 1b dosing planned Q3 2023.
TN-301 MAD stage dosing commenced; Phase 1 data from SAD/MAD expected H2 2023.
TN-401 (PKP2 gene therapy) IND submission planned for H2 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tenaya Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2022 results: net income Net loss was $33.5 million, or $0.61 loss per share for the fourth quarter ended December 31, 2022. For the full year 20.

Period: the fourth quarter and full year ended December 31, 2022
Net income: Net loss was $33.5 million, or $0.61 loss per share for the fourth quarter ended December 31, 2022. For the full year 20
Result: reported results

Exact text from the filing

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

View on SEC.gov

Browse all earnings releases →

Tenaya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-006713

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.